Basit öğe kaydını göster

dc.contributor.authorAvcı, Muhittin Eftal
dc.contributor.authorArslan, Ferhat
dc.contributor.authorÇiftci, Şinasi
dc.contributor.authorEkiz, Ali
dc.contributor.authorTüten, Abdullah
dc.contributor.authorYıldırım, Gökhan
dc.contributor.authorMadazlı, Rıza
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:58:32Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:58:32Z
dc.date.issued2016en_US
dc.identifier.citationAvcı, M. E., Arslan, F., Çiftci, Ş., Ekiz, A., Tüten, A., Yıldırım, G. ... Madazlı, R. (2016). Role of spiramycin in prevention of fetal toxoplasmosis. Journal Of Maternal-Fetal & Neonatal Medicine, 29(13), 2073-2076. https://dx.doi.org/10.3109/14767058.2015.1074998en_US
dc.identifier.issn1476-7058
dc.identifier.issn1476-4954
dc.identifier.urihttps://dx.doi.org/10.3109/14767058.2015.1074998
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3188
dc.descriptionWOS: 000374773800006en_US
dc.descriptionPubMed ID: 26365472en_US
dc.description.abstractObjective: The aim of this study is to evaluate the efficacy of spiramycin in prevention of mother-to-child transmission of Toxoplasma gondii infection. Methods: Patients within first trimester of their pregnancy with Toxoplasma IgM positivity (>0.65 index, ELISA, VIDAS) and IgG positivity (>8 IU/ml), who had low IgG avidity (<0.50 index, ELISA, Architet) were considered as having acute toxoplasmosis. These patients who had amniocentesis at the 19th-21st week of pregnancy were examined for the detection of Toxoplasma DNA. Detailed ultrasonographic examinations performed between the 20th and 24th gestational weeks and the mothers and babies were followed for at least one year. Results: Out of 61 patients, 55 (90.2%) had received Spy prophylaxis while 6 (9.8%) cases refused Spy prophylaxis. Toxoplasma PCR test was found to be positive in amniotic fluid of 4 (6.6%) patients obtained by amniocentesis at the 19th-21st week of pregnancy. All four of these patients had refused Spy prophylaxis had positive Toxoplasma PCR in amniotic fluid (p<0.01). Conclusion: Our results seem to encourage the use of spiramycin in women with toxoplasmosis during pregnancy.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAmniocentesisen_US
dc.subjectPCRen_US
dc.subjectProphylaxisen_US
dc.subjectSpiramycinen_US
dc.subjectToxoplasma Gondiien_US
dc.titleRole of spiramycin in prevention of fetal toxoplasmosisen_US
dc.typearticleen_US
dc.relation.ispartofJournal Of Maternal-Fetal & Neonatal Medicineen_US
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Ana Bilim Dalıen_US
dc.authorid0000-0001-8554-7651en_US
dc.identifier.volume29en_US
dc.identifier.issue13en_US
dc.identifier.startpage2073en_US
dc.identifier.endpage2076en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.doi10.3109/14767058.2015.1074998en_US
dc.identifier.wosqualityQ3en_US
dc.identifier.scopusqualityQ2en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster